Caris MPI is a TechBio company founded in 2008 that combines molecular profiling, blood-based diagnostics, and artificial intelligence to inform cancer treatment decisions. The company's core offering - molecular profiling - generates comprehensive blueprints of individual tumours, revealing their unique molecular characteristics. This foundation has evolved into a suite of products including MI Profile for tumour profiling, MI Cancer Seek for blood-based cancer diagnostics, and Caris ChromoSeq, which provides whole genome and whole transcriptome sequencing.
The company's approach rests on integrating large volumes of consistently generated molecular data with AI-driven analysis to produce actionable insights for physicians and patients. By combining tumour profiling with blood-based diagnostics and machine-learning technologies, Caris MPI aims to translate molecular complexity into clinically useful treatment guidance. The company operates at the intersection of molecular science and data analytics, working across the oncology and precision medicine sectors.
Caris MPI's team comprises scientific and medical professionals focused on transforming how cancer care decisions are made through data-driven, personalised insights grounded in each patient's molecular profile.
